MedTrace Logo

First in Patient Study for PF-06840003 in Malignant Gliomas

NCT02764151 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2020-01-27

Study results available
· View outcomes & findings →

Summary

This study will evaluate the safety and tolerability of increasing doses of PF-06840003 in patients with malignant gliomas.

Conditions

Interventions

DRUG

PF-06840003

Daily Oral PF-06840003

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-09
Primary Completion
2018-12-26
Completion
2018-12-26

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02764151 on ClinicalTrials.gov